Request a Quote
Skip to main content

Posts

Showing posts with the label peginterferon alfa-2b

Pegylated interferon alpha for chronic hepatitis B and D

Pegylated interferon alpha is a finite-course, resistance-free choice for selected patients living with chronic viral hepatitis. In October 2025 the national medical-products regulator approved peginterferon alfa-2b combined with nucleos(t)ide analogs for adult chronic hepatitis B patients with sustained HBsAg clearance, the first interferon indication cleared on a clinical-cure endpoint. A hepatitis D antibody approved in January 2026 changed the treatment order there without ending interferon's role, while hepatitis C has mostly moved to interferon-free regimens. Background: why one drug sits in three different places Interferon is not a single antiviral drug. It is a class of immune modulators, and how well it works leans heavily on the patient's own immune state. That is why pegylated interferon alpha reads as a retired drug in hepatitis C, a returning first-line choice in hepatitis B, and one of two options in hepatitis D. Chronic hepatitis C: already off the first line Di...